IBSA Institut Biochimique SA

Aesthetic medicine aims to improve and maintain the aesthetic well-being of the skin, through a precise analysis of the general and local conditions of the patient, the formulation of accurate diagnoses and the development of therapeutic strategies.

IBSA offers a complete range of products based on the concept of Hydrolift® Action, an innovative approach aimed at counteracting the physiological decrease of the hyaluronic acid (HA) naturally present in the skin, thus restoring its hydration, elasticity and tone.

In recent years, the line has been expanded with an innovative product containing a solution of thermally stabilised ultrapure hyaluronic acid hybrid cooperative complexes developed with IBSA’s patented hybrid Nahyco® technology.

Across Europe, around 500 million working days are lost each year due to chronic and acute pain, resulting in a huge social and economic impact.

Among the different remedies available for the symptomatic treatment of pain, non-steroidal anti-inflammatory drugs (NSAIDs) have been, and still are, widely used.

In the area of pain and inflammation, IBSA offers various types of products for topical, oral and transdermal use.

Hypothyroidism is one of the most common chronic disorders, affecting up to 5% of the global population and requiring thyroid hormone replacement therapy.

For the treatment of hypothyroidism, IBSA developed innovative liquid and soft capsule formulations of hormones and supplements.

Patients with recurrent Urinary Tract Infections (rUTI), Interstitial Cystitis (IC/BPS), or cystitis from radiotherapy or chemotherapy suffer from urothelial damage, which causes severe pain and inflammation.

IBSA offers several types of hyaluronic acid-based products in pre-filled syringes and soft capsules that help prevent damage to the urothelium, while improving its healing process. The company also focuses on male disorders, such as Erectile Dysfunction (ED), with the innovative oral formulation in orodispersible film (ODF).

In the last two decades, interest in omega-3 Polyunsaturated Fatty Acids (PUFA) has grown, thanks to their antidyslipidemic, anti-inflammatory, antiarrhythmic and antithrombotic properties.

In addition to being introduced in the diet, omega-3s, extracted from fish oil, can be prescribed by doctors as drugs in case of certain chronic conditions. IBSA uses omega-3 fatty acids (EPA/DHA), which have been certified as a sustainable source by the NGO Friends of the Sea and have obtained the IFOS Five Star certification for their purity, freshness and concentration.

Within the dermatological area, IBSA developed a portfolio of hyaluronic acid-based products obtained through a patented and certified bio-fermentation process.

The line of hyaluronic acid-based products is completed by cosmetic products (a spray and a gel formulation) indicated for skin irritations of various origins (wind, sun, cold, sweat, shaving, beauty treatments and tattoos). 

In the Consumer Health area, IBSA has developed several solutions to better address the small challenges to which the body is exposed every day.

In terms of mortality, incidence and costs, respiratory diseases are second only to cardiovascular conditions.

Globally, hundreds of millions of people suffer from chronic respiratory diseases. Climate change is probably responsible for several negative effects on our health, as described by WHO.

In Europe and in the rest of the world, mortality from chronic respiratory and lung diseases is expected to increase in the future. IBSA offers a range of mucolytics and other products containing hyaluronic acid, indicated as an adjuvant treatment for several chronic conditions.

Infertility is a female and male disease defined by the inability to achieve pregnancy after 12 months or more of regular sexual intercourse.

Approximately 17.5% of the adult population, or one in six people worldwide, suffer from infertility, highlighting the urgent need to increase access to fertility care (WHO).

Infertility, therefore, has an undeniable social dimension and cannot be relegated, as is often the case, to a minority of couples left to address their issues alone. IBSA is one of the major players within reproductive medicine, offering a portfolio of products for the treatment of infertility, including progesterone in aqueous solution and extractive gonadotropins, which are highly glycosylated thanks to a unique purification process.

Osteoarticular conditions – which affect about 10% of the world population – occur in two forms: inflammatory and degenerative.

They are usually characterised by a chronic evolution which, if left untreated, can lead to irreversible damage to the joint structures, leading to disability and invalidity.

In the osteoarticular area, IBSA offers several types of products, to be taken orally or intra-articularly.